McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, WI, United States of America.
University of Wisconsin Carbone Cancer Center, Madison, WI, United States of America.
PLoS One. 2021 Nov 4;16(11):e0259245. doi: 10.1371/journal.pone.0259245. eCollection 2021.
Anal squamous cell carcinoma (SCC) will be diagnosed in an estimated 9,080 adults in the United States this year, and rates have been rising over the last several decades. Most people that develop anal SCC have associated human papillomavirus (HPV) infection (~85-95%), with approximately 5-15% of anal SCC cases occurring in HPV-negative patients from unknown etiology. This study identified and characterized the Kras-driven, female sex hormone-dependent development of anal squamous cell carcinoma (SCC) in the LSL-KrasG12D; Pdx1-Cre (KC) mouse model that is not dependent on papillomavirus infection. One hundred percent of female KC mice develop anal SCC, while no male KC mice develop tumors. Both male and female KC anal tissue express Pdx1 and Cre-recombinase mRNA, and the activated mutant KrasG12D gene. Although the driver gene mutation KrasG12D is present in anus of both sexes, only female KC mice develop Kras-mutant induced anal SCC. To understand the sex-dependent differences, KC male mice were castrated and KC female mice were ovariectomized. Castrated KC males displayed an unchanged phenotype with no anal tumor formation. In contrast, ovariectomized KC females demonstrated a marked reduction in anal SCC development, with only 15% developing anal SCC. Finally, exogenous administration of estrogen rescued the tumor development in ovariectomized KC female mice and induced tumor development in castrated KC males. These results confirm that the anal SCC is estrogen mediated. The delineation of the role of female sex hormones in mediating mutant Kras to drive anal SCC pathogenesis highlights a subtype of anal SCC that is independent of papillomavirus infection. These findings may have clinical applicability for the papillomavirus-negative subset of anal SCC patients that typically respond poorly to standard of care chemoradiation.
预计今年美国将有 9080 名成年人被诊断为肛门鳞状细胞癌 (SCC),而且在过去几十年中,发病率一直在上升。大多数患有肛门 SCC 的人都有相关的人乳头瘤病毒 (HPV) 感染 (~85-95%),大约有 5-15%的肛门 SCC 病例发生在 HPV 阴性的患者中,其病因不明。本研究在 LSL-KrasG12D; Pdx1-Cre (KC) 小鼠模型中确定并描述了由 Kras 驱动、女性性激素依赖性的肛门鳞状细胞癌 (SCC) 的发展,该模型不依赖于乳头瘤病毒感染。100%的雌性 KC 小鼠会发展为肛门 SCC,而没有雄性 KC 小鼠发生肿瘤。雄性和雌性 KC 肛门组织均表达 Pdx1 和 Cre 重组酶 mRNA 以及激活的突变 KrasG12D 基因。尽管驱动基因突变为 KrasG12D 存在于雌雄两性的肛门中,但只有雌性 KC 小鼠会发展为 Kras 突变诱导的肛门 SCC。为了了解性别依赖性差异,对 KC 雄性小鼠进行了去势,对 KC 雌性小鼠进行了卵巢切除术。去势的 KC 雄性小鼠表现出未发生肛门肿瘤形成的未改变表型。相比之下,卵巢切除的 KC 雌性小鼠肛门 SCC 的发展明显减少,只有 15%的小鼠发生肛门 SCC。最后,外源性雌激素给药挽救了卵巢切除的 KC 雌性小鼠的肿瘤发展,并诱导了去势的 KC 雄性小鼠的肿瘤发展。这些结果证实了肛门 SCC 是由雌激素介导的。女性性激素在介导突变 Kras 以驱动肛门 SCC 发病机制中的作用的描述突出了一种独立于 HPV 感染的肛门 SCC 亚型。这些发现可能对 HPV 阴性的肛门 SCC 患者亚组具有临床适用性,这些患者通常对标准的放化疗反应不佳。